Edesa Biotech Inc. [NASDAQ: EDSA] stock went on a downward path that fall over -16.49% on Friday, amounting to a one-week price decrease of less than -24.38%. The company report on February 26, 2021 that Edesa Biotech Increases Previously Announced Bought Deal Offering of Common Shares to $10.0 Million.
Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 1,562,500 common shares of Edesa, at a price to the public of $6.40 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about March 2, 2021, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
Over the last 12 months, EDSA stock rose by 104.44%.
The market cap for the stock reached $72.97 million, with 10.28 million shares outstanding and 6.46 million shares in the current float. Compared to the average trading volume of 605.19K shares, EDSA stock reached a trading volume of 1666603 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Edesa Biotech Inc. [EDSA]:
The Average True Range (ATR) for Edesa Biotech Inc. is set at 0.82, with the Price to Sales ratio for EDSA stock in the period of the last 12 months amounting to 364.87. The Price to Book ratio for the last quarter was 7.17.
EDSA Stock Performance Analysis:
Edesa Biotech Inc. [EDSA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -24.38. With this latest performance, EDSA shares dropped by -9.51% in over the last four-week period, additionally sinking by -7.38% over the last 6 months – not to mention a rise of 104.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EDSA stock in for the last two-week period is set at 42.01, with the RSI for the last a single of trading hit 35.97, and the three-weeks RSI is set at 45.32 for Edesa Biotech Inc. [EDSA]. The present Moving Average for the last 50 days of trading for this stock 5.70, while it was recorded at 6.25 for the last single week of trading, and 5.85 for the last 200 days.
Insight into Edesa Biotech Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Edesa Biotech Inc. [EDSA] shares currently have an operating margin of -1946.72 and a Gross Margin at +77.14. Edesa Biotech Inc.’s Net Margin is presently recorded at -1935.59.
Return on Total Capital for EDSA is now -88.11, given the latest momentum, and Return on Invested Capital for the company is -88.03. Return on Equity for this stock declined to -88.61, with Return on Assets sitting at -77.24. When it comes to the capital structure of this company, Edesa Biotech Inc. [EDSA] has a Total Debt to Total Equity ratio set at 1.80. Additionally, EDSA Total Debt to Total Capital is recorded at 1.77, with Total Debt to Total Assets ending up at 1.53. Long-Term Debt to Equity for the company is recorded at 1.42, with the Long-Term Debt to Total Capital now at 1.02.
Reflecting on the efficiency of the workforce at the company, Edesa Biotech Inc. [EDSA] managed to generate an average of -$530,353 per employee. Receivables Turnover for the company is 2.16 with a Total Asset Turnover recorded at a value of 0.04.Edesa Biotech Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 8.50.
EDSA Stock EPS
With the latest financial reports released by the company, Edesa Biotech Inc. posted -0.17/share EPS, while the average EPS was predicted by analysts to be reported at -0.19/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EDSA.
Edesa Biotech Inc. [EDSA] Insider Position Details
There are presently around $1 million, or 20.70% of EDSA stock, in the hands of institutional investors. The top three institutional holders of EDSA stocks are: FNY INVESTMENT ADVISERS, LLC with ownership of 75,000, which is approximately -37.711% of the company’s market cap and around 5.10% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 74,100 shares of the stock with an approximate value of $0.41 million in EDSA stocks shares; and STIFEL FINANCIAL CORP, currently with $0.13 million in EDSA stock with ownership of nearly 50.003% of the company’s market capitalization.
Positions in Edesa Biotech Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 5 institutional holders increased their position in Edesa Biotech Inc. [NASDAQ:EDSA] by around 112,210 shares. Additionally, 5 investors decreased positions by around 49,835 shares, while 4 investors held positions by with 52,213 shares. The mentioned changes placed institutional holdings at 214,258 shares, according to the latest SEC report filing. EDSA stock had 2 new institutional investments in for a total of 96,591 shares, while 2 institutional investors sold positions of 3,127 shares during the same period.